A detailed history of Virtus ETF Advisers LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 179,972 shares of LXRX stock, worth $127,780. This represents 0.14% of its overall portfolio holdings.

Number of Shares
179,972
Previous 179,972 -0.0%
Holding current value
$127,780
Previous $302,000 6.62%
% of portfolio
0.14%
Previous 0.15%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.54 - $2.28 $174,204 - $257,913
-113,120 Reduced 38.6%
179,972 $302,000
Q1 2024

May 15, 2024

BUY
$1.3 - $3.58 $54,819 - $150,965
42,169 Added 16.81%
293,092 $703,000
Q4 2023

Feb 15, 2024

BUY
$1.0 - $1.53 $129,212 - $197,694
129,212 Added 106.16%
250,923 $383,000
Q3 2023

Nov 07, 2023

SELL
$1.06 - $2.33 $16,683 - $36,671
-15,739 Reduced 11.45%
121,711 $132,000
Q2 2023

Aug 14, 2023

BUY
$2.15 - $3.49 $295,517 - $479,700
137,450 New
137,450 $314,000
Q2 2022

Aug 12, 2022

SELL
$1.31 - $2.69 $51,433 - $105,614
-39,262 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$1.95 - $3.89 $4,527 - $9,032
-2,322 Reduced 5.58%
39,262 $82,000
Q4 2021

Feb 14, 2022

SELL
$3.81 - $6.16 $10,645 - $17,211
-2,794 Reduced 6.3%
41,584 $164,000
Q3 2021

Nov 15, 2021

SELL
$3.38 - $5.35 $7,844 - $12,417
-2,321 Reduced 4.97%
44,378 $213,000
Q2 2021

Aug 10, 2021

BUY
$4.12 - $5.87 $192,399 - $274,123
46,699 New
46,699 $214,000
Q2 2020

Aug 05, 2020

SELL
$1.75 - $2.3 $211,872 - $278,461
-121,070 Closed
0 $0
Q1 2020

May 14, 2020

SELL
$1.8 - $4.28 $18,388 - $43,724
-10,216 Reduced 7.78%
121,070 $236,000
Q4 2019

Feb 13, 2020

BUY
$3.16 - $5.15 $27,277 - $44,454
8,632 Added 7.04%
131,286 $545,000
Q3 2019

Nov 12, 2019

SELL
$1.2 - $6.66 $24,741 - $137,315
-20,618 Reduced 14.39%
122,654 $369,000
Q2 2019

Aug 13, 2019

BUY
$5.35 - $7.11 $766,505 - $1.02 Million
143,272 New
143,272 $901,000
Q1 2019

May 14, 2019

SELL
$4.36 - $7.94 $358,806 - $653,422
-82,295 Closed
0 $0
Q4 2018

Feb 05, 2019

BUY
$6.15 - $10.51 $132,637 - $226,669
21,567 Added 35.51%
82,295 $546,000
Q3 2018

Nov 14, 2018

BUY
$10.32 - $13.06 $42,229 - $53,441
4,092 Added 7.23%
60,728 $648,000
Q2 2018

Aug 10, 2018

SELL
$7.8 - $13.69 $259,030 - $454,631
-33,209 Reduced 36.96%
56,636 $680,000
Q1 2018

May 14, 2018

SELL
$7.86 - $11.39 $41,139 - $59,615
-5,234 Reduced 5.5%
89,845 $770,000
Q4 2017

Feb 14, 2018

BUY
$8.77 - $12.28 $663,073 - $928,453
75,607 Added 388.29%
95,079 $939,000
Q3 2017

Nov 14, 2017

BUY
$12.17 - $16.3 $21,674 - $29,030
1,781 Added 10.07%
19,472 $239,000
Q2 2017

Aug 14, 2017

BUY
N/A
17,691
17,691 $291,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $134M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.